Secondly, the direct mechanism of POC1A in tumour immunity has not been conclusively confirmed, and its relationship with drug sensitivity remains a theoretical prediction which may necessitate validation through animal experiments and clinical trials. This evidence concerns the gene POC1A and neoplasm.